To boost the tumor bed: The age of reason;Complément d'irradiation du lit tumoral: l'Áge de raison

Cancer/Radiotherapie

Volumn 8, Issue 1, 2004, Pages 33-38

  Maingon, P ^a   Chapet, O ^b   Barillot, I ^a   Romestaing, P ^b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Boost technique; Breast cancer; Prognostic factors; Radiotherapy

Indexed keywords

PROGESTERONE RECEPTOR;

AGE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; ESTHETICS; FIBROSIS; GENETIC ANALYSIS; HUMAN; INTRADUCTAL CARCINOMA; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT INDICATION;

EID: 1242338748     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2003.09.002     Document Type: Short Survey

References (33)

1. Arriagada R., Mouriesse H., Sarrazin D., et al. Radiotherapy alone in breast cancer I analysis of tumor parameters, tumor dose and local control: the experience of the Gustave Roussy Institute and the Princess Margareth Hospital. Int J Radiat Oncol Biol Phys. 11:1985;1751-1757.
2. Bartelink H., Borger J.H., Van Dongen J.A., Peterse J.L. The impact of tumor size and histology on local control after breast conservative therapy. Radiother Oncol. 11:1988;297-303.
3. Bartelink H., Horiot J.C., Poortmans P., Struikmans H., Van den Bogaert W., Barillot I., et al. European Organization For Research and Treatment of Cancer Radiotherapy and Breast Group. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. New Engl. J. Med. 345:2001;1378-1387.
4. Benda R.K., Yasuda G., Gabram S.G.A., Hinerman R.W., Mendenhall N.P. Breast boost: are we missing the target ? A comparison of two boost techniques. Cancer. 97:2003;905-909.
5. Borger J.H., Kemperman H., Smitt H.S., Hart A., Van Dongen J., Bartelink H. Risk factors in breast conservation therapy. J Clin Oncol. 12:1994;653-660.
6. Edmundson G.K., Vicini F.A., Chen P.Y., Mitchell C., Martinez A.A. Dosimetric characteristics of the MammoSite RTS, a new breast brachytherapy applicator. Int J Radiat Oncol Biol Phys. 52:(4):2002;1132-1139.
7. Fischer B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation in the treatment of invasive breast cancer. New Engl J Med. 347:2002;1233-1241.
8. Fourquet A., Campana F., Mosseri V., Cetingoz R., Luciani S., Labib A., et al. Iridium-192 versus Cobalt60 boost in 3-7 cm breast cancer treated with breast conserving therapy. Radiother Oncol. 34:1995;114-120.
9. Fowble B.L., Schultz D.J., Overmoyer B., Solin L.J., Fox K., Jardines L. The influence of young age on outcome in early breast cancer. Int J Radiat Oncol Biol Phys. 30:1994;23-33.
10. Fowble B.L. The relationship between local relapse an distant metastases revisited. Int J Radiat Oncol Biol Phys. 30:1994;237-239.
11. Gage I., Schnitt S.J., Nixon A.J., Silver B., Recht A., Troyan S.L., et al. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer. 78:(9):1996;1921-1928.
12. Haffty B.G., Carter D., Flynn S.D., Fisher D.B., Brash D.E., Simons J. Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys. 27:1993;575-583.
13. Haffty B.G., Fisher D.B., Rose M., Beinfield M., McKhann C. Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data. J Clin Oncol. 9:1991;997-1003.
14. Hennequin C., Durdux C., Espie M., Balla-Mekias S., Housset M., Marty M., Chotin G., Maylin C. High-dose-rate brachytherapy for early breast cancer: an ambulatory technique. Int J Radiat Oncol Biol Phys. 45:(1):1999;85-90.
15. Holland R., Connolly J.L., Gelman R., Mravunac M., Hendricks J.C.H.L., Cerbeek A.L.M. The presence of an extensive intra-ductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol. 8:1990;113-118.
16. Kovner F., Agay R., Merimsky O., Stadler J., Klausner J., Inbar M. Clips and scar as the guidelines for breast radiation boost after lumpectomy. Eur J Surg Oncol. 25:1999;483-486.
17. Krawczyk J.J., Engel B. The importance of surgical clips for adequate tangential beam planning in breast conserving surgery and irradiation. Int J Radiat Oncol Biol Phys. 43:1999;347-350.
18. Kurtz J.M., Jacquemier J., Amalric R., Brandone H., Ayme Y., Hans D. Why are local recurrences after breast conserving surgery more frequent in younger patients. J Clin Oncol. 8:1990;591-598.
19. Machay M., Lanciano R., Hoffman J., Hanks G.E. Inaccuracies in using the lumpectomy scar for planning electron boost in primary breast carcinoma. Int J Radiat Oncol Biol Phys. 30:1994;43-48.
20. Park C.C., Mitsumori M., Nixon A., Recht A., Connolly J., Gelman R., et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 18:(8):2000;1668-1675.
21. Polgar C., Fodor J., Orosz Z., Major T., Takacsi-Nagy Z., Mangel L.C., et al. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial. Strahlenther Onkol. 178:(11):2002;615-623.
22. Romestaing P., Lehingue Y., Carrie C., Cocquard R., Montbarbon X., Ardiet J.M., et al. Role of a 10 Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 15:(3):1997 Mar;963-968.
23. Schnitt S.J., Abner A., Gelman R., Connolly J.L., Recht A., Duda R.B., et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer. 74:(6):1994;1746-1751.
24. Touboul E., Belkacemi Y., Lefranc J.P., Uzan S., Ozsahin M., Korbas D., et al. Early breast cancer: influence of type of boost (electrons vs iridium-192 implant) on local control and cosmesis after conservative surgery and radiation therapy. Radiother Oncol. 34:1995;105-113.
25. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 19:(347(25)):2002;1999-2009.
26. Van Dongen J.A., Bartelink H., Fentiman I.S., Lerut T., Mignolet F., Olt G., et al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancers. Eur J Cancer. 28A:(4-5):1992;801-805.
27. Veronesi U., Banfi A., Salvadori P., Luini A., Saccozzi R., Zucali R. Breast conservation is a treatment of choice in small breast cancer : long term results of randomized trial. Eur. J. Cancer. 26:1990;668-670.
28. Vicini F.A., Eberlain T.J., Connolly J.L. The optimal extent of resection for patients with stage I or II breast cancer treated with conservative surgery and radiotherapy. Ann Surg. 214:1991;200-204.
29. Voogd A.C., Nielsen M., Peterse J.L., Blichert-Toft M., Bartelink H., Overgaard M., et al. Differences in risk factors for local and distant recurrence of breast conserving therapy or mastectomy for stage I or II breast cancer: pooled results of two large European random trials. J. Clin Oncol. 19:2001;1688-1697.
30. Vrieling C., Collette L., Bartelink E., Borger J.H., Brenninkmeyer S.J., Horiot J.C., et al. Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys. 1:(45(3)):1999;667-676.
31. Vrieling C., Collette L., Fourquet A., Hoogenraad W.J., Horiot J.H., Jager J.J., et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol. 55:(3):2000 Jun;219-232.
32. Vrieling C., Collette L., Fourquet A., Hoogenraad W.J., Horiot J.C., Jager J.J., et al. Can patient-treatment and pathology related characteristics explain the high local recurrence rate following breast conserving therapy in young patients. Eur.J.Cancer. 39:2003;932-944.
33. Wazer D.E., Kramer B., Schmid C., Ruthazer R., Ulin K., Schmidt-Ullrich R. Factors determining outcome in patients treated with interstitial implantation as a radiation boost for breast conservation therapy. Int J Radiat Oncol Biol Phys. 9:1997;381-393.